These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 15046536)

  • 21. Noradrenaline and serotonin reuptake inhibition as clinical principles: a review of antidepressant efficacy.
    Humble M
    Acta Psychiatr Scand Suppl; 2000; 402():28-36. PubMed ID: 10901156
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of effects of dual transporter inhibitors on monoamine transporters and extracellular levels in rats.
    Koch S; Hemrick-Luecke SK; Thompson LK; Evans DC; Threlkeld PG; Nelson DL; Perry KW; Bymaster FP
    Neuropharmacology; 2003 Dec; 45(7):935-44. PubMed ID: 14573386
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differences in mechanism of action between current and future antidepressants.
    Stahl SM; Grady MM
    J Clin Psychiatry; 2003; 64 Suppl 13():13-7. PubMed ID: 14552651
    [TBL] [Abstract][Full Text] [Related]  

  • 24. SSRIs and SNRIs: broad spectrum of efficacy beyond major depression.
    Gorman JM; Kent JM
    J Clin Psychiatry; 1999; 60 Suppl 4():33-8; discussion 39. PubMed ID: 10086481
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of co-administration of varenicline and antidepressants on extracellular monoamine concentrations in rat prefrontal cortex.
    Rollema H; Wilson GG; Lee TC; Folgering JH; Flik G
    Neurochem Int; 2011 Jan; 58(1):78-84. PubMed ID: 21056607
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Two actions are better than one: avoiding self-inhibition of serotonergic neurones enhances the effects of serotonin uptake inhibitors.
    Romero L; Bel N; Casanovas JM; Artigas F
    Int Clin Psychopharmacol; 1996 Sep; 11 Suppl 4():1-8. PubMed ID: 8923121
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Efficacy of atypical antipsychotics in depressive syndromes].
    Quintin P; Thomas P
    Encephale; 2004; 30(6):583-9. PubMed ID: 15738862
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder.
    Foster RH; Goa KL
    CNS Drugs; 1997 Aug; 8(2):163-88. PubMed ID: 23338224
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recent developments in the design of anti-depressive therapies: targeting the serotonin transporter.
    Butler SG; Meegan MJ
    Curr Med Chem; 2008; 15(17):1737-61. PubMed ID: 18673223
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of new antidepressants.
    Sambunaris A; Hesselink JK; Pinder R; Panagides J; Stahl SM
    J Clin Psychiatry; 1997; 58 Suppl 6():40-53. PubMed ID: 9227672
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Triple uptake inhibitors: therapeutic potential in depression and beyond.
    Chen Z; Skolnick P
    Expert Opin Investig Drugs; 2007 Sep; 16(9):1365-77. PubMed ID: 17714023
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of selective serotonin and norepinephrine reuptake inhibitors on depressive- and impulsive-like behaviors and on monoamine transmission in experimental temporal lobe epilepsy.
    Kumar U; Medel-Matus JS; Redwine HM; Shin D; Hensler JG; Sankar R; Mazarati A
    Epilepsia; 2016 Mar; 57(3):506-15. PubMed ID: 26813337
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The noradrenergic action in antidepressant treatments: pharmacological and clinical aspects.
    Dell'Osso B; Palazzo MC; Oldani L; Altamura AC
    CNS Neurosci Ther; 2011 Dec; 17(6):723-32. PubMed ID: 21155988
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety concerns associated with the use of serotonin reuptake inhibitors and other serotonergic/noradrenergic antidepressants during pregnancy: a review.
    Tuccori M; Testi A; Antonioli L; Fornai M; Montagnani S; Ghisu N; Colucci R; Corona T; Blandizzi C; Del Tacca M
    Clin Ther; 2009 Jun; 31 Pt 1():1426-53. PubMed ID: 19698902
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical and biochemical effects of catecholamine depletion on antidepressant-induced remission of depression.
    Miller HL; Delgado PL; Salomon RM; Berman R; Krystal JH; Heninger GR; Charney DS
    Arch Gen Psychiatry; 1996 Feb; 53(2):117-28. PubMed ID: 8629887
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synaptic effects of antidepressants.
    Richelson E
    J Clin Psychopharmacol; 1996 Jun; 16(3 Suppl 2):1S-7S; discussion 7S-9S. PubMed ID: 8784643
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake inhibitor.
    Wong EH; Sonders MS; Amara SG; Tinholt PM; Piercey MF; Hoffmann WP; Hyslop DK; Franklin S; Porsolt RD; Bonsignori A; Carfagna N; McArthur RA
    Biol Psychiatry; 2000 May; 47(9):818-29. PubMed ID: 10812041
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Venlafaxine: a novel antidepressant that has a dual mechanism of action.
    Andrews JM; Ninan PT; Nemeroff CB
    Depression; 1996; 4(2):48-56. PubMed ID: 9160640
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacology of rapid-onset antidepressant treatment strategies.
    Blier P
    J Clin Psychiatry; 2001; 62 Suppl 15():12-7. PubMed ID: 11444761
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Emerging mechanisms and treatments for depression beyond SSRIs and SNRIs.
    Dale E; Bang-Andersen B; Sánchez C
    Biochem Pharmacol; 2015 May; 95(2):81-97. PubMed ID: 25813654
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.